NL300960I2 - Combinatie van daunorubicine en cytarabine - Google Patents

Combinatie van daunorubicine en cytarabine Download PDF

Info

Publication number
NL300960I2
NL300960I2 NL300960C NL300960C NL300960I2 NL 300960 I2 NL300960 I2 NL 300960I2 NL 300960 C NL300960 C NL 300960C NL 300960 C NL300960 C NL 300960C NL 300960 I2 NL300960 I2 NL 300960I2
Authority
NL
Netherlands
Prior art keywords
cytarabine
daunorubicin
combination
Prior art date
Application number
NL300960C
Other languages
English (en)
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of NL300960I2 publication Critical patent/NL300960I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
NL300960C 2004-04-22 2018-12-11 Combinatie van daunorubicine en cytarabine NL300960I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
PCT/CA2005/000625 WO2005102359A1 (en) 2004-04-22 2005-04-22 Liposomal formulations of anthracycline agents and cytidine analogs

Publications (1)

Publication Number Publication Date
NL300960I2 true NL300960I2 (nl) 2019-05-22

Family

ID=35196733

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300960C NL300960I2 (nl) 2004-04-22 2018-12-11 Combinatie van daunorubicine en cytarabine

Country Status (12)

Country Link
US (2) US8022279B2 (nl)
EP (2) EP1744764B1 (nl)
JP (1) JP4972545B2 (nl)
AU (1) AU2005235455B2 (nl)
CA (1) CA2564542C (nl)
CY (2) CY1113012T1 (nl)
ES (1) ES2388064T3 (nl)
HK (1) HK1097194A1 (nl)
IL (1) IL178779A (nl)
NL (1) NL300960I2 (nl)
PT (1) PT1744764E (nl)
WO (1) WO2005102359A1 (nl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213183A1 (en) * 2004-09-20 2008-09-04 Marcel Bally Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
PT2120568T (pt) 2007-02-16 2017-12-04 Celator Pharmaceuticals Inc Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
BR112014009305B1 (pt) 2011-10-21 2023-01-24 Celator Pharmaceuticals Inc. Composição lipossomal de fase gel liofilizada
HUE038744T2 (hu) 2012-04-04 2018-11-28 Halozyme Inc Kombinációs terápia hialurodinázzal és egy tumor-targetált taxánnal
CA3122808A1 (en) 2012-05-09 2013-11-14 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
WO2016177741A1 (en) 2015-05-04 2016-11-10 Eth Zurich Method for preparing transmembrane ph-gradient vesicles
EP3372223B1 (en) * 2015-11-02 2024-04-17 FUJIFILM Corporation Liposome composition and method for producing same
AU2016353163B2 (en) 2015-11-11 2022-09-29 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP7305613B2 (ja) * 2017-07-09 2023-07-10 バイオサイト リミテッド 併用がん療法
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (nl) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7238367B2 (en) * 2001-10-03 2007-07-03 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
JP2006522026A (ja) * 2003-04-02 2006-09-28 セレーター ファーマスーティカルズ、インク． カンプトセシンとフルオロピリミジンとを組み合わせた組成物
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations

Also Published As

Publication number Publication date
WO2005102359A1 (en) 2005-11-03
IL178779A (en) 2013-12-31
EP1744764A4 (en) 2009-04-01
CY2018033I2 (el) 2019-07-10
CY2018033I1 (el) 2019-07-10
US8022279B2 (en) 2011-09-20
PT1744764E (pt) 2012-08-30
JP2007533670A (ja) 2007-11-22
ES2388064T3 (es) 2012-10-08
HK1097194A1 (en) 2007-06-22
WO2005102359A8 (en) 2005-12-15
AU2005235455B2 (en) 2011-01-20
JP4972545B2 (ja) 2012-07-11
CA2564542C (en) 2012-11-27
US20120009252A1 (en) 2012-01-12
IL178779A0 (en) 2007-05-15
EP1744764A1 (en) 2007-01-24
AU2005235455A1 (en) 2005-11-03
CA2564542A1 (en) 2005-11-03
EP2407169A1 (en) 2012-01-18
EP1744764B1 (en) 2012-05-30
CY1113012T1 (el) 2016-04-13
US8431806B2 (en) 2013-04-30
US20070286897A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
NL300960I2 (nl) Combinatie van daunorubicine en cytarabine
NL301185I2 (nl) Combinatie van daunorubicine en cytarabine
EP1644729A4 (en) ANTI-CD74 immunoconjugates and methods
ZA200803153B (en) Antibody-drug conjugates and methods of use
EP1863389A4 (en) TISSUE HANDLING AND FASTENING SYSTEM
PT2578685T (pt) Arn contendo nucleósidos modificados e os seus métodos de utilização
DE602004017351D1 (de) Fft-architektur und -verfahren
ZA200709043B (en) Benzodioxane and benzodioxalane derivatives and uses thereof
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
EP1921105A4 (en) MODIFIED HYDROPHILIC POLYROTAXAN AND NETWORKED POLYROTAXANE
EP1951682A4 (en) NEW 2-AMINOPYRIMIDONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE
AP2006003699A0 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
DE602006003063D1 (de) Tripeptid- und tetrapeptidsulfone
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
EP1816130A4 (en) NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF
GB0413868D0 (en) Dimensional anlaysis of saccharide conjugates
GB0411387D0 (en) Analysis of saccharide length
DK1958948T3 (da) Pyridazinforbindelse og anvendelse deraf
DE112006002272T8 (de) Katheter und Katheter-Kit
IL192047A0 (en) Organ preservation and/or perfusion
DK2119472T3 (da) Hud-/hårbehandlingssystem
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
EP1978999A4 (en) ISOLATED MCPIP PROTEIN AND METHODS OF USE
EP1878754A4 (en) PREPARATION AND APPLICATION OF SILVER HEPARINE